For Patients

DRCR Protocol AG

Randomized Clinical Trial Assessing the effects of Pneumatic Vitreolysis on Vitroemacular Traction (Protocol AG)
South Region Patients
We are taking part in a study to determine the effects of a new treatment on a condition called Vitreomacular Traction (VMT).
This study is being conducted by the DRCR Network, which is a group of clinical sites dedicated to research of retinal diseases. This Network includes over 100 eye centers in the United States and Canada.
Primary Objective: To compare the proportion of eyes with foveal VMT (symptomatic VMA) release on OCT after PVL with gas injection vs. observation (sham injection) in eye with VMT with-out an associated macular hole.

Secondary Objective: To evaluate visual function outcomes at 24 weeks after gas injection is performed compared with observation.
There will be two groups: PVL (injection of C3F8 gas) and Observation (Sham Injection).
Time in study 24 wks and patients will be using myVisionTrack. A password will be provided to all patients to use the myVisionTrack app with the patients' own password on phones and tablets at home.
There is rescue therapy of a Vitrectomy.
Optional Aqueous Sample collection and consent. To enroll in this study and for more detailed information, please click here.

DRCR Protocol AH

Single-Arm Study Assessing the Effects of Pneumatic Vitreolysis on Macular Hole (Protocol AH)
South Region Patients
We are taking part in a study to determine the effects of a new treatment on a condition called a macular hole. This study is being conducted by the DRCR Network, which is a group of clinical sites dedicated to research of retinal diseases.Objective: To obtain estimates for the proportion of eye with macular hole closure of the inner retinal layers for eye with VMT and full-thickness macular holes treated with PVL.
The treatment used in this study is a gas called perfluoropropane or C3F8. Injections into the eye of C3F8 gas have been approved by the U.S. Food and Drug Administration for a procedure called Pneumatic Retinopexy, which is a treatment for certain types of retinal detachment. These C3F8 gas injections into the eye have been used by retina specialists for more than 30 years to treat retinal detachment. Gas injections have not been approved for treating macular holes. Therefore, gas injections in this study are considered experimental. Injection of the gas bubble has been used in some patients with macular holes as an alternative to surgery.
Time in study 24 weeks.
There is rescue therapy of a Vitrectomy.
Optional Aqueous Sample collection and consent.
Panda-Chengdu Kanghong Biotechnology
A Multi-Center, Doubled-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration

Time in study 96 wks. Conbercept functions as a VEGF-antagonist, it is being developed for the treatment of VEGF-associated CNV originating from wet AMD. To enroll in this study and for more detailed information, please click here.

Protocol GO29665

South Region Patients

A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously treated Solid Tumors. This study is in conjunction with Orlando Health, Arnold Palmer Hospital for Health. Closed for enrollment but actively seeing current patients for 4 years-duration of study. For more detailed information about this study, please click here.

Protocol KHB-1801 (Chengdu)

South Region Patients

A Multi-Center, Double Masked, Randomized, Dose-Ranging Trial to Evaluate Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration. wAMD is a leading cause of severe and irreversible vision loss. When left untreated, wAMD can progress, causing damage to the retina that may lead to scarring and loss of central vision. The Panda study is one way for you to assist researchers in their search to discover effective new treatments for wAMD. For more detailed information about this study, please click here.

DRCR Protocol W

South Region Patients

Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk. A multi-center study being conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) sponsored by the National Institutes of Health, the U.S. Department of Health and Human Services. For more detailed information about this study, please click here.

DRCR Protocol AC

North and South Region Patients

Intravitreous Aflibercept vs. Intravitreous Bevacizumab + Deferred Aflibercept for treatment of Central-Involved Diabetic Macular Edema. A multi-center study being conducted by the Diabetic Retinopathy Clinical Research Network sponsored by the National Institutes of Health, the U.S. Department of Health and Human Services. For more detailed information about this study, please click here.

DRCR Protocol GEN-Genetics in Retinal Diseases

North Region Patients

To better understand the effects of diabetes on the retina, the Diabetic Retinopathy Clinical Research Network (DRCR.net) is collecting a blood sample from people with diabetes. The blood sample will be used to extract DNA. DNA is the part of a cell that contains unique genetic information. It is hoped that through studies done on the DNA, scientists will develop a better understanding of how diabetes causes changes in the retina and how diabetic retinopathy can best be treated. For more detailed information about this study, please click here.

DRCR Protocol GBV-102-002 (ALTISSIMO STUDY for Macular Degeneration)

South Region Patients

The ALTISSIMO clinical research study is evaluating the safety and effectiveness of an investigational drug in people living with neovascular (wet) age-related macular degeneration (AMD). In this study, the investigational drug will be compared to a drug currently used for treating wet AMD. For more detailed information about this study, please click here.

Protocol #BI 1467335 (1386.12) ROBIN Study

South Region Patients

A Randomized, Double masked, Placebo-controlled exploratory study to evaluate tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 weeks with a 12- week follow up period in patients with Non-Proliferative Diabetic Retinopathy without Center-Involved Diabetic Macular Edema (ROBIN Study). For more detailed information about this study, please click here.

Are you interested in a new study and ready to enroll?

Contact Us More Study Information

New patients interested in enrolling in this study, please send us an E-mail. Include your name, the reason of your interest in this study and the office location you receive treatment. You will receive a reply from us within 48 - 72 hours.